11/27/21, 5:31 AM RePORT) RePORTER

∢ Back to Search Results

Description







Publications

Patents

Outcomes

Clinical Studies

News and More

History

Similar Projects

Development of an H2O2-inactivated chikungunya virus vaccine

Project Number Contact PI/Project Leader 5R44AI128990-03 AMANNA, IAN JAMES Other PIs

Awardee Organization NAJIT TECHNOLOGIES, INC.

⊘° ⊃⊓are ▼



Abstract Text

Chikungunya **virus** (CHIKV) is an alphavirus that has gained significant attention due to its ability to cause large epidemics among susceptible populations and to be spread beyond endemic countries by international travelers. Among a population of approximately 750,000 on the French island of La Reunion, 266,000 people were infected and over 200 CHIKV-related fatalities occurred during the 2006 outbreak. Likewise, an estimated 1.4 million people were infected with CHIKV in India during outbreaks that occurred from 2006 to 2007 and recently there have been more than 1.7 million people infected with CHIKV in the Caribbean and the Americas. At present, there is no commercial vaccine available for CHIKV. The development of an inactivated CHIKV vaccine suitable for immunizing the general population as well as vulnerable groups including infants and the elderly represents an important unmet clinical need. We have developed a versatile vaccine platform based on inactivating viruses with hydrogen peroxide (H2O2) and here, we present preclinical efficacy data demonstrating that our optimized prototype H2O2-CHIKV vaccine can provide complete protection against infection and CHIKV-associated pathology in a robust mouse model. Based on this innovative new approach to vaccine development and promising preclinical data with CHIKV, we propose a detailed research plan to perform all necessary IND-enabling studies and to manufacture clinical-grade H2O2-inactivated CHIKV vaccine suitable for Phase I trials.

Public Health Relevance Statement

PUBLIC HEALTH RELEVANCE There is currently no vaccine available to combat chikungunya virus, a pathogen that causes debilitating and sometimes lethal infection. Our advanced technology for developing a safe and effective H2O2-inactivated chikungunya virus vaccine represents a new approach to this unmet clinical need.

NIH Spending Category

Biodefense Biotechnology Emerging Infectious Diseases Immunization Infectious Diseases

Orphan Drug Prevention Rare Diseases Vaccine Related Vector-Borne Diseases

Project Terms

Alphavirus Americas Antibody Response Arthritis Attention Attenuated Attenuated Vaccines Awareness Caribbean region **Case Fatality Rates Cessation of life** Chikungunya virus Clinical **Clinical Immunology Clinical Virology Consultations** Country Culicidae Cyclic GMP **Detection Disease Disease Outbreaks Data Development Ebola virus Europe Formulation Ebola Vaccines Elderly Epidemic Foundations Fever General Population** Growth Hemorrhage **Hepatitis A Virus Hydrogen Peroxide** Goals In Vitro **Inactivated Vaccines Immunity Immunology** India Industry Infant **Immunize** Infection Infrastructure International Japanese encephalitis virus Knowledge Island

Read More

Details

Contact PI/ Project Leader

Name

AMANNA, IAN JAMES

Title

VP FOR RESEARCH

Contact

iamanna@najittech.com

Other Pls

Name

SLIFKA, MARK K

Program Official

Name

DUPUY, LESLEY CONRAD

Contact

lesley.dupuy@nih.gov

Organization

Name Department Type

Thank you for your feedback!

11/27/21, 5:31 AM RePORT) RePORTER

▼ Back to Search Results

Description



Sub-Projects



Patents



Outcomes

Clinical Studies

News and More

<u>History</u>

Similar Projects

Development of an H2O2-inactivated chikungunya virus vaccine

Contact PI/Project Leader Project Number Awardee Organization 5R44AI128990-03 **AMANNA, IAN JAMESOther Pls NAJIT TECHNOLOGIES, INC.**

Other Information

FOA Administering Institutes or Centers PAR-14-088 AND INFECTIOUS DISEASES Study Section

Special Emphasis Panel ZRG1-IMM-<u>R(12)B</u>]

Fiscal Year Award Notice Date 2019 07-February-2019

NATIONAL INSTITUTE OF ALLERGY

DUNS Number CFDA Code 147965243 855

Project Start Date

01-March-2017

01-March-2019

Project End Date 28-February-

2022

Budget Start

Date

Budget End Date 28-February-

2022

Project Funding Information for 2019

Total Funding Direct Costs Indirect Costs \$989,109 \$0 \$0

FY Total Cost by IC Funding IC Year 2019 NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES \$989,109

NIH Categorical Spending

Click here for more information on NIH Categorical Spending

Funding IC	FY Total Cost by IC	NIH Spending Category
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES	\$989,109	Biodefense; Biotechnology; Emerging Infectious Diseases; Immunization; Infectious Diseases; Orphan Drug; Prevention; Rare Diseases; Vaccine Related: Vector-Borne Diseases:

品 Sub Projects

No Sub Projects information available for 5R44Al128990-03

Publications

No Publications available for 5R44AI128990-03

Patents

No Patents information available for 5R44Al128990-03

Outcomes

The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.

No Outcomes available for 5R44Al128990-03

Clinical Studies

No Clinical Studies information available for 5R44Al128990-03

11/27/21, 5:31 AM RePORT) RePORTER

∢ Back to Search Results

Development of an H2O2-inactivated chikungunya virus vaccine

Description

Project Number 5R44AI128990-03 **Contact PI/Project Leader AMANNA, IAN JAMESOther Pls** **Awardee Organization NAJIT TECHNOLOGIES, INC.**

Details

Sub-Projects

Patents

Publications History

Outcomes

Clinical Studies

News and More

<u>History</u>

Similar Projects

No Historical information available for 5R44Al128990-03

Similar Projects

No Similar Projects information available for 5R44Al128990-03